Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.
about
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.HIV-1 Integrates Widely throughout the Genome of the Human Blood Fluke Schistosoma mansoni.Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection.Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.HIV persistence: clonal expansion of cells in the latent reservoir.Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies.Exosomes from uninfected cells activate transcription of latent HIV-1.Unusual Fusion Proteins of HIV-1Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro.Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety.HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.HIV: Persistence through division.HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.Reactivation of HIV-1 proviruses in immune-compromised mice engrafted with human VOA-negative CD4+ T cells.Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants.Brain-specific HIV Nef identified in multiple patients with neurological disease.Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.HIV integration sites and implications for maintenance of the reservoir.What do we measure when we measure cell-associated HIV RNA.Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA.Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained.The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery.Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.HIV latency reversing agents act through Tat post translational modifications.Total HIV DNA: a global marker of HIV persistence.Sex Differences in HIV Infection: Mystique Versus MachismoVisualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected CellsPhenotype, Polyfunctionality, and Antiviral Activity of Stimulated CD8 T-Cells From HIV Subjects Who Initiated cART at Different Time-Points After Acute InfectionHIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction
P2860
Q33585386-0F0B0F34-70A2-4809-B9B8-89A25644F062Q36169656-BE946C91-3E78-4420-93AF-1DFEDFD35728Q36274030-060BEE4A-DD1C-4EFC-9DA9-8CC753520807Q37415458-103E7222-7D24-4730-9A80-2F915788F3CDQ37737052-8A843B00-F300-41FE-84AA-C516E0254761Q38660421-18272E6C-B3C0-4639-B698-ACA6AE97E9D5Q38669409-0A672D73-77C6-49D3-ABBB-FBBF59EE552BQ38682297-9A2C22AE-9A0D-4D18-8C48-AAA08E440875Q38702490-E935EAB3-A043-4A1F-A364-5F9099B8A6FFQ39101871-6C2B97C5-1D8C-4A6B-8027-80CDE54E0750Q39315703-E270D8A4-5D15-41F1-806A-B1C9ED21B601Q39362365-B3623AA1-8E54-4904-880E-2A440A2CEBCCQ40054912-EE4E28E5-6418-4A34-9EB7-1B8F67A62551Q40077663-051E5968-9158-4338-A1D0-B7AECADF44B8Q40080802-3BCAE58E-7645-4AEC-9290-AC56893C258FQ40239429-FC1911B0-7B31-4EAD-9C30-7CE89C0E26F8Q40266878-D116C562-27E6-4B03-BC88-2E30CCEDF125Q40271315-5849FEF0-EC91-43D4-9A34-5F38F0813779Q40339502-E3F5A645-4E11-4CA1-A6BD-2D064860A226Q41933638-D134A358-E8F2-4AA4-94ED-8F887D270427Q42318286-0E479255-96C7-4289-A292-2F7237CEAF6EQ46281767-354911D6-69A4-4C9C-BC41-7ABE342CC81AQ46365036-E4732036-40E3-44CD-AFA9-61DBE37EB081Q47199601-E227F1A0-E369-46B9-8D20-8EDFBC565ABFQ47329569-C36DAA76-80D6-4AC3-BB44-588CB968BA9BQ47548192-FA3E85DE-F6F5-49DD-85C3-3D3D98019905Q47549310-DB773217-1677-4BA1-9C04-B5C8CD2DD2B1Q47550536-2FCEF6EF-A49C-4F6D-BBB1-4E5968CA1C82Q47552344-0C07D8C8-2BD5-4031-8143-3F7A417E6A51Q48113493-565F48C8-120E-4AB5-97B8-631699DB08E5Q49298325-CD1E7FB4-F1BB-4545-B690-D38813110550Q49920984-FBBC34E4-C68A-4ED8-AF1C-DAAF8924240CQ50282032-DF34C584-DFB0-45FA-93B1-B2F182A7FFA5Q52657975-B541315F-41BE-4F3D-ABEC-E3945C4F8924Q54214251-BD2CC67B-CAEF-4A08-BC7F-570978843D2BQ54242626-1DF71806-8054-41BD-AF07-007A46389843Q56996082-13EBB74D-2248-4A58-8A12-CA35CF34648EQ57064408-902676D7-7FE1-4FBC-9A2F-88AFA27A0A49Q58572549-AD06837E-BD7E-4EC8-84ED-FA516D2E4FC7Q58701373-5FF1389E-C985-4361-A571-0A4B8DCAB179
P2860
Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@en
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@nl
type
label
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@en
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@nl
prefLabel
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@en
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@nl
P2093
P2860
P921
P356
P1476
Defective HIV-1 proviruses pro ...... nation antiretroviral therapy.
@en
P2093
Catherine A Rehm
Ellen E Paxinos
Hiromi Imamichi
Joseph W Adelsberger
Robin L Dewar
Una O'Doherty
P2860
P304
P356
10.1073/PNAS.1609057113
P407
P577
2016-07-18T00:00:00Z